![]() |
|
|
Vol. 54, Issue 2, 364-371, August 1998
Institut National de la Santé et de la Recherche Médicale U 151, CHU Rangueil, Bat L3, 31403 Toulouse Cedex, France (S.S.-P., C.E.), and Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804
| |
Summary |
|---|
|
|
|---|
The cholecystokinin (CCK) receptor types A and B (CCKAR and CCKBR) are G protein-coupled receptors with approximately 50% amino acid identity; both have high affinity for the sulfated CCK octapeptide (CCK-8), whereas only the CCKBR has high affinity for gastrin. Previously, we identified five amino acids in the second extracellular loop (ECL) of the CCKBR that were essential for gastrin selectivity. Subsequent mutagenesis of one of these five amino acids (H207F) resulted in the loss of radiolabeled CCK-8 binding. CCK-8 stimulated total inositol phosphate accumulation in COS-1 cells transiently expressing the CCKBR-H207F with full efficacy and a 3044-fold reduced potency, which suggests that the loss of radioligand binding was caused by a loss in affinity. Alanine scanning mutagenesis was performed on the amino terminus near the top of transmembrane domain I (TMI) and on ECL1, two extracellular domains implicated in ligand binding by previous mutagenesis studies. 125I-Bolton-Hunter-CCK-8 binding to mutant receptors transiently expressed in COS-1 identified one nonconserved amino acid, R57A, at the top of TMI that caused a 21-fold reduction in CCK-8 affinity and four conserved amino acids, N115A, L116A, F120A and F122A, in the ECL1 that caused a 15.6-, 6-, 440-, and 8-fold reduction in affinity or efficacy. Alanine substitution of the equivalent amino acids in the CCKAR corresponding to each of the five amino acids in ECL1 and ECL2 affecting CCK-8 affinity for the CCKBR revealed only two mutations, L103A and F107A, that decreased CCK-8 affinity (68- and 2885-fold, respectively). These data suggest that CCK-8 interacts at multiple contact points in the extracellular domains of CCK receptors and that the CCKAR and CCKBR have distinct binding sites despite their shared high affinity for CCK-8.
| |
Introduction |
|---|
|
|
|---|
CCK
is a regulatory peptide hormone found predominately in localized
endocrine cells of the gastrointestinal tract and neurotransmitter present throughout the nervous system. CCK is processed from a 115-amino-acid preprohormone to multiple molecular fragments. CCK-8 and
larger forms (CCK-58, CCK-39 and CCK-33, CCK-22) have similar high
affinity for the two pharmacological receptor subtypes, CCKA and CCKB.
The shorter CCK forms (CCK-4 to CCK-7) have a lower affinity and are
able to discriminate CCKA and CCKB receptors displaying a higher
affinity for the CCKBR (Poirot et al., 1993
; Wank, 1995
).
The CCKBR can also be highly discriminated by the selective affinity
for the related gastrin family of peptides that share the same
carboxyl-terminal pentapeptide-amide but differ in sulfation at the
sixth (gastrin) versus the seventh (CCK) tyrosyl residue. The full
biological activity of CCK peptides reside in the carboxyl-terminal
sulfated, amidated heptapeptide. CCK acting through the CCKAR and the
CCKBR has well-characterized physiological and pharmacological
functions. In the gastrointestinal system, CCK regulates motility,
pancreatic enzyme secretion and growth, gastric emptying, and
inhibition of gastric acid secretion. In the nervous system, CCK is
involved in anxiogenesis, satiety, analgesia, and regulation of
dopamine release (Crawley and Corwin, 1994
).
Although the pharmacology and actions of CCK receptors have been well
studied and their possible implication in disorders related to their
functions reported (Crawley and Corwin, 1994
), much less is known about
the structural basis for the interaction of CCK agonists with both the
CCKAR and the CCKBR subtypes. The cloning of CCKAR and CCKBR has shown
that CCK receptors are seven transmembrane G protein-coupled receptors
that have ~ 50% amino acid homology (Wank et al.,
1992a
, 1992b
). Despite the relatively high degree of homology and
shared affinity for CCK-8, a study of the human CCKBR undertaken to
evaluate the role of the nonconserved transmembrane domain amino acids
for agonist and antagonist selectivity identified three amino acid
residues, R57Q, S219H, and H376L, that decrease CCK affinity 6-, 5-, and 29-fold, respectively, when mutated to the corresponding CCKAR
amino acids (Kopin et al., 1995
). However, mutation of H381
in the rat CCKBR, (equivalent to H376 in the human CCKBR) to Leu did
not change the affinity for CCK-8 (Jagerschmidt et al.,
1996
). For the CCKAR, it has been reported that the amino-terminal
domain of the CCKAR in rat and human is important for CCK-9 binding
(Poirot et al., 1994
; Kennedy et al., 1995
). In
this region, two nonconserved residues in the human CCKAR (W39 and Q40)
caused a decrease of 12.9- and 20.9-fold in CCK-9 affinity,
respectively, after conservative mutations (W39F, Q40N). Furthermore,
these residues were shown to affect CCK-8 binding by interacting with
the amino terminus of CCK-8 (Kennedy et al., 1997
). In the
course of a previous study that permitted us to identify a segment of
five amino acids (residues 204-208; Fig.
1, bottom) in the ECL2 of the
rat CCKBR that was essential for the high affinity and selectivity of
gastrin binding (Poirot and Wank, 1996
), we observed that the binding
of radiolabeled CCK-8 was lost when we substituted a block of amino
acids (amino acid residues 204, 206-209; Fig. 1, bottom) in
the ECL2 with the corresponding amino acids of the CCKAR (Fig. 1,
top). Further mutations in the ECL2 revealed that the
substitution of H207F alone could account for this loss of affinity.
The importance of H207 in ECL2 for CCK-8 binding indicated that the
extracellular domains of the CCKBR were involved in CCK-8 binding,
which was consistent with our previous studies aimed at determining the importance of this region for gastrin selectivity. Previously, no
studies have evaluated the role of the extracellular domains of the
CCKBR for CCK-8 binding affinity. Therefore, based on our previous data
that demonstrates the importance of this single amino acid substitution
H207F in the ECL2, the present work was undertaken to evaluate the
previously undetermined role of the first ECL1 and amino-terminal
region in CCK-8 binding to the CCKBR and compare these findings with
those for the corresponding positions in the CCKAR. These regions were
chosen because they are likely to be proximal to H207 in the ECL2 of
the CCKBR by virtue of a putative disulfide bridge shown for other G
protein-coupled receptors (Karnik et al., 1988
) and the
demonstrated importance of amino-terminal region for CCK-8 binding to
the CCKAR (Poirot et al., 1994
; Kennedy et al.,
1995
, 1997
).
|
Using an alanine scanning mutagenesis approach (Hjorth et
al., 1994
; Leong et al., 1994
; Huang et al.,
1995
; Kim et al., 1995
; Mouillac et al., 1995
),
we report that a mutation at the top of TMI (R57A), four mutations in
the first ECL (N115A, L116A, F120A, and F122A), and a mutation in the
second ECL (H207A) resulted in decreased CCKBR affinity for the
agonist, CCK-8. When these mutations were made in the equivalent
positions of the CCKAR, only two, L103A and F107A in the first ECL of
the CCKAR, affected CCK-8 affinity. Unlike the CCKAR, no mutations in
the distal amino terminus (proximal to the top of TMI) of the CCKBR had
an affect on CCK-8 affinity. These results indicate that although the
extracellular domains of both the CCKBR and CCKAR significantly
contribute to CCK-8 binding, CCK-8 does not interact with all
equivalently positioned amino acids. Consistent with the observed
selectivity of shorter CCK forms for the CCKBR, these results suggest
that the CCK-8 binding site differs in the two receptor subtypes
despite their shared high affinity for CCK-8.
| |
Materials and Methods |
|---|
|
|
|---|
Construction of mutant receptor.
cDNAs-mutant
receptor cDNAs were constructed by oligonucleotide-directed
mutagenesis (Muta-Gene Phagemid in vitro Mutagenesis Kit,
Bio-Rad, Hercules, CA), using the CCKBR or the CCKAR cDNAs as a single
strand template as described previously (Poirot and Wank, 1996
).
Oligonucleotides were designed to include a silent restriction site to
facilitate analysis of mutant constructs by restriction endonuclease
digestion. Mutations were confirmed by DNA sequencing using the dsDNA
Cycle Sequencing System (Gibco BRL, Gaithersburg, MD) or using the Dye
Terminator kit and an automated 377 DNA Sequencer (Applied Biosystems,
Norwalk, CT).
Transfection of wild-type and mutant receptor cDNAs into
mammalian cells.
COS-1 cells were grown in DMEM supplemented with
10% fetal calf serum. Two micrograms of the CCKBR, CCKAR and mutant
receptor cDNAs subcloned in pCDL-SR
was transiently transfected into
COS-1 cells using the DEAE/Dextran method as described previously
(Poirot and Wank, 1996
). Twenty-four hours after transfection, the
transfected cells were transferred to 24-wells culture plates and
seeded at a density of approximately 1 × 105 cells/well and assayed for radioligand
binding or IP hydrolysis.
Radioligand binding to transfected COS-1 cells.
Twenty-four
hours after the transfer of transfected cells to 24-well plates, the
cells were washed once with cold PBS, pH 7.4, containing 0.1% BSA and
incubated in DMEM containing 0.1% BSA for 60 min at 37° with either
50 pM of 125I-BH-CCK-8 (2200 Ci/mmol)
or 1.8 nM [3H]SR27897 (31 Ci/mmol)
(Gully et al., 1993
) or for 30 min with 0.4 nM
[3H]PD140,376 (51 Ci/mmol) with and without the
indicated concentrations of unlabeled ligand. The cells were washed two
times with PBS containing 2% BSA and were collected with 0.5 ml of 0.1 N NaOH added to each well and radioactivity detected in
either a
or
counter (Packard, Downers Grove, IL). Nonspecific
binding (determined in presence of 1 µM CCK-8) was always
less than 10% of total binding. Binding assays were performed in
duplicate in at least three separate experiments.
Kd and
Bmax values were determined using the
nonlinear least-squares curve-fitting computer program, Ligand (Munson
and Rodbard, 1980
).
Measurement of total IP accumulation.
Twenty-four hours
after COS-1 cell transfection, the transfected cells were transferred
to 24-well culture plates and incubated overnight in DMEM with 3 µCi/well of myo-2-[3H]inositol
(18.6 Ci/mmol)(Dupont-New England Nuclear, Boston, MA). After the
aspiration of the medium containing the
myo-[3H]inositol, the cells were
incubated at 37° for 20 min with 2 ml of PBS, pH 7.45, containing 20 mM LiCl, incubated 1 hr at 37° with IP buffer (20 mM HEPES, 135 mM NaCl, 2 mM CaCl2,
1.2 mM MgSO4, 1 mM EGTA)
containing the indicated concentrations of CCK-8. The reaction was
stopped with 1 ml of methanol/HCl added to each well and the content
transferred to a Dowex AG 1-X8 (formate form) column (Bio-Rad,
Hercules, CA). Each column was washed with 5 ml of water followed by 2 ml of 5 mM sodium tetraborate/60 mM sodium
formate. Total IP were eluted from the columns with 2 ml of 1 M ammonium formate/100 mM formic acid. The
total [3H]IP
-radioactivity was detected in
a liquid scintillation counter (Packard).
Immunofluorescence assay.
A peptide epitope, YPYDVPDYA, from
the hemagglutinin of the influenza virus (HA1) was fused to the amino
terminus of the wild-type CCKBR and the mutant CCKBRs, C127A-CCKBR and
C205A-CCKBR, using the polymerase chain reaction (Field et
al., 1988
) The day after the transient transfection into COS-1
cells, 1.25 × 105 cells were transferred to
Lab-Tek chambered coverglass slides for tissue culture (Nunc,
Naperville, IL). Two days after transfection, cells were washed two
times with PBS and fixed with 2% formaldehyde in PBS for 15 min at
room temperature. To permeabilize the cell membranes, cells were
treated with 0.1% saponin in PBS (w/v) for 10 min. After washing with
PBS three times and blocking with DMEM containing 10% fetal calf
serum, cells were incubated with 12CA5 monoclonal antibody at 10 mg/ml
(BAbCo, Richmond, CA) for 3 hr at 37°. The cells were subsequently
washed with PBS and incubated with a 1/100 dilution of a fluorescein
isothiocyanate-conjugated anti-mouse IgG antibody (Sigma, St. Louis,
MO) in DMEM containing 10% fetal calf serum for 1 hr at 37°. After
washing with PBS, the cells were analyzed on a confocal laser scanning
microscope (LSM 410; Carl Zeiss, Thornburg, NY).
| |
Results |
|---|
|
|
|---|
In a previous study of chimeric CCKA and CCKB receptors, we
determined that a segment of five amino acids (amino acid residues 204, 206-209; Fig. 1, bottom) in the ECL2 was responsible for conferring gastrin-17-I selectivity (Poirot and Wank, 1996
). In the course of our studies, it was observed that the binding of radiolabeled CCK-8 was lost when a block of amino acids (amino acid
residues 204, 206, and 207; Fig. 1, bottom) in the ECL2 was substituted with the corresponding amino acids of the CCKAR, whereas other segment substitutions elsewhere in the ECL2 had no effect on
CCK-8 affinity. To determine which of the three amino acids in this
segment of the ECL2 could account for this loss of affinity for CCK-8,
each was individually mutated to the corresponding amino acid in the
CCKAR. These mutants and wild-type CCKBR were transiently expressed in
COS-1 cells and their affinity for CCK-8 was determined by radioligand
binding inhibition studies using 125I-BH-CCK-8.
These studies revealed that the substitution H207F alone could account
for this loss of affinity and that reciprocal mutations of amino acids
Q204 and M206 with the corresponding CCKAR amino acids did not
significantly change CCK-8 affinity. The
Kd obtained was 1.03 (± 0.05)
nM for the mutant CCKBR-Q204 M and 0.65 (± 0.12) nM for
the mutant CCKBR-M206R compared with 0.46 (± 0.08)
nM for the wild-type CCKBR. In the absence of
detectable binding of a 50 pM concentration of
125I-BH-CCK-8 by the mutant CCKBR-H207F, we
measured CCK-8 stimulated total IP production to determine if this
mutant was functionally expressed. The mutant receptor, CCKBR-H207F,
increased total IP with full efficacy relative to the wild-type CCKBR
(11-fold increase over basal), although the dose-response curve was
displaced 3044-fold to the right compared with the wild-type CCKBR
(Fig. 2) with EC50 values of 1016 (±406) nM and 0.33 (±0.07)
nM, respectively. Consistent with the fully
efficacious stimulation of total IP by the CCKBR-H207F mutant,
Scatchard analysis of the CCKBR specific nonpeptide antagonist, [3H]PD 140376, binding revealed a similar level
of expression of the CCKBR-H207F mutant
(Bmax = 3.95 ± 0.34 pmol/106 cells) compared with wild-type CCKBR
(Bmax = 4.33 ± 0.26 pmol/106 cells). To determine whether the loss of
CCK binding for the mutant CCKBR-H207F was caused by an unfavorable
interaction peculiar to the side chain of the substituted Phe residue,
we mutated the His residue to an Ala. Similar to the mutant
CCKBR-H207F, the mutant CCKBR-H207A displayed no detectable binding of
125I-BH-CCK8, indicating that the side chain of
the Phe residue was not uniquely responsible for the loss of CCK
binding. These data suggest that the loss of
125I-BH-CCK8 binding was caused by a substantial
reduction in CCK-8 affinity rather than a loss in receptor expression
and that H207 is critical for conferring high affinity for CCK-8.
|
Conserved cysteines in the first extracellular loop at the top of TM
III and in the ECL2 (C127 and C205; Fig. 1, bottom) are likely to form a disulfide bridge in the CCKBR similar to other G
protein-coupled receptors (Karnik et al., 1988
). This would then bring ECL1 in proximity to H207 in the ECL2, shown above to be
important for high affinity CCK-8 binding. To assess this hypothetical
role for C127 and C205, the two cysteines were individually mutated to
alanine and the effect on CCK-8 affinity was determined. No binding of
CCK-8 was detected for both mutants at a 50 pM
concentration of 125I-BH-CCK-8.
Immunofluorescence studies using an antibody directed against the
hemagglutinin HA1 epitope fused to the amino terminus of the wild-type
and the C127A and C205A CCKB receptors were used to determine if the
respective receptors were expressed at the cell surface of transiently
transfected COS-1 cells. Unlike the wild-type receptor-expressing cells
that exhibited a fluorescent signal at the cell surface, the mutant
C127A-CCKBR and C205A-CCKBR transfected cells exhibited a fluorescent
signal in the intracellular compartment only when the cells were
permeabilized with saponin (data not shown). In addition, CCK-8 was
unable to stimulate an increase in total IP in cells expressing the
mutant C127A-CCKBR and C205A-CCKBR. These results indicate that the
CCKBR mutants C127A and C205A are important for the proper folding and
surface expression of the CCKB receptor and are consistent with the
formation of a disulfide bridge that would bring the ECL1 and the ECL2
closer together.
Subsequently, the role of the first extracellular loop in CCK binding was investigated. To evaluate the possible influence of the ECL1 on CCK-8 affinity, alanine scanning mutagenesis was applied to conserved and nonconserved amino acids in the first extracellular loop (except G118, which was mutated to Lys). All amino acids were mutated except P114 and G123 that are conserved in both the CCKAR and the CCKBR in all species and are felt to have at best an indirect structural affect on ligand binding on the basis of studies with other G protein-coupled receptors. Nonconserved amino acids were included having found that a nonconserved amino acid residue, H207, in the ECL2 was important for the high affinity CCK-8 binding. Nonetheless, mutating each of these nonconserved amino acid residues in the ECL1 did not significantly affect the affinity of CCK-8 relative to the wild-type CCKBR with each mutation exhibiting less than a 3-fold decrease in CCK-8 affinity (Table 1). In contrast, mutation of four conserved amino acids, N115A, L116A, F120A, and F122A, resulted in a significant decrease in CCK-8 affinity. Substitution of L116A and F122A led to a moderate reduction in CCK affinity of 6.2-fold (Kd = 2.94 (±0.84) nM) and 8-fold (Kd = 3.74 (±0.25) nM), respectively, whereas the mutation of N115A caused a more pronounced 15.6-fold (Kd = 7.33 (±1.46) nM) decrease in CCK-8 affinity (Table 1). For the mutant F120A, there was no detectable binding of CCK-8 using a 50 pM concentration of 125I-BH-CCK-8. However, this mutant retained full efficacy (11-fold increase over basal) for signaling CCK-8 stimulated increase in total IP, although the EC50 was reduced 440-fold (EC50 = 147 (±38) nM for the F120A mutant compared with 0.33 (±0.07) nM for the wild-type CCKBR)(Fig. 3). Consistent with the fully efficacious stimulation of total IP by the CCKBR-F120A mutant, Scatchard analysis of the CCKBR specific nonpeptide antagonist, [3H]PD 140376, binding revealed a similar level of expression of the CCKBR-F120A mutant (Bmax = 2.04 ± 1.37 pmol/106 cells) compared with wild-type CCKBR (Bmax = 4.33 ± 0.26 pmol/106 cells). These results indicate that the mutation F120A in the CCKBR results in a major loss in CCK-8 affinity that cannot be attributed to a nonspecific effect resulting in either a loss in receptor expression or a major disruption in receptor conformation.
|
|
A recent report has shown that two nonconserved amino acids, W39 and
Q40, in the amino-terminal region of the CCKAR interact with the amino
terminus of CCK-8 to affect high affinity binding (Kennedy et
al., 1997
). Therefore, to determine the potential role of the
corresponding area of the CCKBR, we first mutated the equivalent amino
acids in the CCKB receptor (amino acid residues L52 and E53) and the
amino acids adjacent to these two positions. Each amino acid was
individually substituted to alanine with the exception of A55, which
was mutated to Leu. For the wild-type CCKBR, the
Kd value obtained for CCK-8 affinity
was 0.46 (±0.08) nM (Table
2). For the mutants CCKBR-L52A and
CCKBR-E53A, the Kd value was 0.50 (±0.22) nM and 0.94 (±0.05)
nM, respectively, indicating that CCK affinity
was not significantly affected (Table 2). To determine if this region
of the CCKBR was important for CCK-8 binding as shown previously for
the CCKAR, we evaluated the role of the amino acid residues neighboring
these two positions. Similarly, the mutations of residues E51A and M54A
did not affect the affinity for CCK-8, the
Kd values were 0.57 (±0.17)
nM and 0.74 (±0.21) nM for
the respective mutants (Table 2). A report of a small decrease of
6-fold in CCK-8 affinity when R57 in the CCKBR was substituted to Gln,
the equivalent amino acid in CCKAR (6), prompted the mutation of amino
acids further down TMI of the CCKBR. Mutations of A55L, I56A, and I58A
did not affect CCK-8 affinity, the Kd
values obtained were 0.30 (±0.17) nM, 0.99 (±0.20) nM, and 0.60 (±0.33)
nM, respectively (Table 2). However, when we
mutated R57 to Ala, we observed a decrease on CCK affinity of 21.3-fold
compared with the wild-type CCKBR. The
Kd value was 9.96 (±0.48)
nM for the mutant CCKBR-R57A compared with 0.46 (±0.08) nM for the wild-type CCKBR (Table 1).
These results indicate that the points of interaction of CCK-8 in this
region of the CCKBR are distinct from the equivalent points of
interaction reported for the CCKAR despite their shared high affinity
for CCK-8.
|
Together, these data show that CCK-8 binding to the CCKBR involve amino
acid residues that are both conserved and divergent from the
corresponding amino acids located in the extracellular regions of the
CCKAR. Having demonstrated that mutation of amino acid residues at
equivalent positions in the amino-terminal domain of the CCKAR and the
CCKBR do not have the same effect on CCK-8 affinity, mutations at
divergent residues shown above to be important for CCK-8 affinity for
the CCKBR were made in the equivalent positions in ECL1 and ECL2 of the
CCKAR to determine their effect on CCK-8 affinity. Residues N102, L103,
F107, and F109 (equivalent to amino acid residues N115, L116, F120, and
F122 in the ECL1 of CCKBR) and amino acid residue F198 (equivalent to
residue H207 in the ECL1 of CCKBR) were mutated to alanine (Fig. 1,
top). Similar to the above studies on the CCKBR, the CCKAR
mutants and the wild-type CCKAR were transiently expressed in COS-1
cells and their affinity for CCK-8 assessed by
125I-BH-CCK-8 radioligand displacement by CCK-8.
Scatchard analysis of 125I-BH-CCK-8 binding on
the wild-type CCKAR results in a single class of high affinity binding
sites as described previously for the CCKAR in COS-1 cells with a
Kd of 0.18 (±0.10)
nM Huang et al., 1994
). The mutants
CCKAR-N102A and CCKAR-F109A displayed a similar affinity for CCK-8
compared with the wild-type CCKAR with a
Kd value of 0.45 (±0.35)
nM and 0.14 (±0.15) nM,
respectively (Table 3). For the mutants
CCKAR-L103A and CCKAR-F107A there was no detectable binding of
125I-BH-CCK-8 using a 50 pM
concentration of radioligand. Using higher ligand concentrations, CCK-8
was able to stimulate these mutant receptors to increase total IP with
an EC50 value that was increased 2885-fold for
the mutant CCKAR-F107A [EC50 = 939 (±133)
nM] and 68.4-fold for the mutant CCKAR-L103A
[EC50 = 22.2 (±6.2) nM]
compared with the wild-type CCKAR [EC50 = 0.325 (±0.034) nM] (Fig.
4). However, both mutants were unable to
induce the same maximum in the IP response compared with the wild-type
CCKAR. The maximum stimulation attained was 77% for the mutant
CCKAR-F107A and 61% for the mutant CCKAR-L103A of the wild-type CCKAR
(18-fold increase over basal) (Fig. 4). To determine whether the lower
efficacy observed for the mutants could be attributable to reduction in receptor expression, Scatchard analysis was performed using the CCKAR-specific nonpeptide antagonist
[3H]SR27897 (Gully et al., 1993
).
These studies revealed a similar affinity and maximal binding capacity
for the two mutants compared with the wild-type CCKAR with
Kd and
Bmax values of 1.52 (±0.23) nM and 0.88 (±0.10)
pmol/106 cells, respectively, for the mutant
CCKAR-F107A, 1.88 (±0.56) nM and 1.65 (±0.22)
pmol/106 cells, respectively, for the mutant
CCKAR-L103A versus 3.96 (±0.02) nM and 1.92 (±0.6) pmol/106 cells, respectively, for the
wild-type CCKAR. These results suggest that the residues F107 and L103
in the ECL1 of the CCKAR play a substantial role in CCK-8 affinity and,
in addition, may participate in the conformational change necessary for
G protein-coupling as indicated by the loss in CCK-8 affinity as well
as the decrease in potency and efficacy for stimulating total IP
observed for the two mutants. In contrast, the affinity of CCK-8 was
not significantly affected for the ECL2 mutant, CCKAR-F198A, having a
Kd value of 0.53 (±0.22)
nM compared with 0.18 (±0.10)
nM for the wild-type CCKAR (Table 3). These
results suggest that F198 is not involved in CCK-8 binding in the CCKAR
although this position seems critical for CCK-8 binding in the CCKBR.
|
|
| |
Discussion |
|---|
|
|
|---|
Previously, chimeric studies between CCKA and CCKB receptors
initially involving large segments and subsequently smaller
site-directed mutations identified five amino acids (Q204, M206, H207,
R208, and W209; Fig. 1, bottom) in the CCKBR conferring
selective high affinity binding for gastrin, a CCK-8 related peptide
sharing the same carboxyl-terminal five amino acids (Poirot and Wank, 1996
). During the course of these experiments, labeled CCK-8 affinity was lost when a group of amino acids (Q204, M206, and H207; Fig. 1,
bottom) in the ECL2 were mutated. It was subsequently
determined that the mutation of only one residue, H207F, could account
for this loss of binding of labeled CCK-8. This loss in CCK-8 binding along with the discovery of nearby amino acids affecting gastrin selectivity suggested that the ECL2 region could be involved in CCK-8
binding. To date, no results have been reported evaluating the role of
the extracellular domains in CCK binding to the CCKBR. Therefore, we
studied further the contribution of H207 to the CCK-8 binding site in
the CCKBR as well as the potential role of five amino acids within two
other proximal extracellular domains, one amino acid in the
amino-terminal extension and top of TMI shown to be important for CCK
binding to both the CCKAR and CCKBR and four amino acids in the ECL1
drawn toward the second extracellular loop by virtue of a putative
disulfide bridge. The probability for disulfide bond formation between
the conserved cysteines in ECL1 at the top of TM III and in the second
ECL (C127 and C205; Fig. 1, bottom) is supported by the loss
of receptor surface expression demonstrated by the absence of
radioligand binding, the loss of CCK-8 stimulated total IP production,
the negative immunolocalization studies after mutation of each of these
cysteines to alanine reported in this study, the loss of affinity for
CCK upon dithiothreitol reduction of CCKB-like receptors from toad
retina (Bone and Rosenzweig, 1988
), and similar findings reported for
other G protein-coupled receptors (Dixon et al., 1987
;
Karnik et al., 1988
; Hulme et al., 1990
).
In the absence of detectable binding of the CCKBR-H207F mutant, the
CCK-8 stimulated increase in total IP was measured for the CCKBR-H207F
mutant expressed transiently in COS-1 cells. The mutant CCKBR-H207F
increased total IPs with full efficacy although the potency was reduced
3044-fold compared with the CCKBR-WT. These data suggest that the
CCKBR-H207F mutation does not lead to misfolding and subsequent reduced
expression and suggests that although a direct affect on ligand binding
cannot be concluded for this loss of function point mutation, the loss
in CCK-8 affinity is not the result of a gross conformational change.
Interestingly, CCKBR-H207 is involved in the sequence of five amino
acids that we determined to be essential for the selective binding of
gastrin in the CCKBR (Poirot and Wank, 1996
). These results suggest
that the ECL2 of the CCKBR is important for both selective and
nonselective agonist binding.
Although the amino-terminal extension of a number of peptide receptors
has been shown to interact with their ligand (Fong et al.,
1992
; Leong et al., 1994
; Hjorth et al., 1994
) as
well as specifically for the CCKAR where the mutation of two
amino-terminal residues (W39 and Q40) were reported to be involved in
CCK binding and to interact directly with the amino-terminal moiety of
CCK-8 (Kennedy et al., 1997
), the reciprocal changes in
CCKBR did not affect the affinity of CCK-8. In fact, the closest
residue from this locus that significantly affects CCK binding was the
residue R57 located at the top of TMI. A 21.3-fold decrease in CCK-8
affinity was observed when R57 was mutated to Ala (Kopin et
al., 1995
). This value is in the same range as the 12.9 and
20.9-fold decrease obtained for the mutation of the residues W39 and
Q40 in the CCKA (Kennedy et al., 1997
). It is also in
agreement with the 6.1 and 10-fold decrease in affinity observed for
the more conservative R57Q CCKB/A chimeric mutant (Kopin et
al., 1995
) and the naturally occurring amino-terminal truncated
isoform,
CCKBR, in which the amino-terminal 66 amino acids are
absent (Miyake, 1995
).
In addition to the residue R57 in the top of TMI and H207 located in
ECL2, four residues, N115, L116, F120, and F122, that significantly
decreased CCK-8 binding in the CCKBR were identified by alanine
scanning mutagenesis in the ECL1. The mutation F120A in ECL1, similar
to H207F in ECL2 of the CCKBR, resulted in a complete loss of
radiolabeled CCK-8 binding and a concomitant reduction in potency for
CCK stimulated IP-response of 440-fold. Also similar to H207A, F120A
reached the same maximal IP response compared with the control CCKBR,
making it unlikely that an indirect effect of this mutation on CCK
affinity was caused by low expression or a gross conformation
alteration. This is an important point, because F120 is within a region
of ECL1 loosely corresponding to a WPXF motif seen in the AT1 and other
7TM receptors, in which mutations lead to loss of function that is
suspected on the basis of alteration in conformation and expression
(Hjorth et al., 1994
). Therefore, this important shift in
the IP response for both mutants along with a relatively small or no
change in receptor expression indicates a strong effect of the
mutations on CCK affinity and suggests that residues H207 and F120 are
important for the high affinity binding of CCK to the CCKBR.
Further supporting the involvement of ECL1 in the ligand binding site
for CCK-8 was the 15.6-, 8-, and 6-fold reduction in affinity as a
result of the N115A, L116A, and F122A mutations in the ECL1,
respectively. Similar to these findings for the CCKBR, point mutations
involving multiple amino acids clustered within a single extracellular
domain have been shown to affect ligand binding for a number of G
protein-coupled receptors (Leong et al., 1994
; Hjorth
et al., 1994
; Huang et al., 1995
; Kennedy
et al., 1997
) and suggest either multiple points of contact
or an indirect effect by multiple amino acids on a single contact point within a limited domain.
The lack of effect of reciprocal mutations in the ECL1 (N102A and
F109A) and ECL2 (F198A) in the CCKAR suggest that all the amino acids
determined to affect CCK-8 affinity in the CCKBR are not necessarily
important for CCK-8 binding in the CCKAR. In fact, of the four
positions that were determined to be important for CCK-8 binding in the
CCKBR, only two positions seem to affect CCK-8 affinity in both the
CCKBR and CCKAR. Only the mutation of residues L103A and F107A both
localized in the ECL1 of the CCKAR induced a strong effect on CCK-8
binding as demonstrated by the loss of radiolabeled CCK-8 binding and
the decrease in potency to stimulate IP of 68.4-fold for the mutant
CCKAR-L103A and 2885-fold for the mutant CCKAR-F107A. In addition,
there was a reduction in the efficacy to stimulate IP production
observed for the mutants CCKAR-L103A and CCKAR-F107A of 39% and 23%,
respectively. In the absence of a reduction in receptor expression at
the cell surface as determined by [3H]SR27897
binding, these results suggest that the mutations L103A and F107A,
unlike their equivalents in the CCKBR, can influence the coupling of
CCKAR to its G protein. Similarly, the lack of effect of the reciprocal
mutations in the proximal amino-terminal extension of the CCKBR suggest
that the two amino acids (W39 and Q40; Fig. 1, top)
previously shown to affect CCK-8 binding to the CCKAR (Kennedy et
al., 1997
) are not necessarily important for CCK-8 binding to the
CCKBR. Although both the CCKAR and the CCKBR have high affinity for the
shared ligand, CCK-8, and therefore might be expected to have similar
binding sites, these data suggest that this is not entirely the case.
As demonstrated in this study, only four of the seven amino acids that
have been shown to affect ligand affinity for either one or both of the
CCK receptors are conserved and only one of these four conserved amino
acids influence binding of CCK to both receptors. In fact, this is not
unusual, because there are several similar examples of G
protein-coupled receptor subtypes with high affinity for the same
ligand in which the binding pocket has not been completely conserved,
such as the neurokinin, angiotensin, dopamine, serotonin, and
somatostatin receptor families (Gingrich and Caron, 1993
; Humphrey
et al., 1993
; Reisine and Bell, 1993
; Hjorth et
al., 1994
).
Initial detailed studies of ligand binding sites in G protein-coupled
receptors pointed to the importance of multiple contact points within
the transmembrane domains as best exemplified by the monoamine ligands
(Schwartz and Rosenkilde, 1996
). Subsequent studies of protein and
peptide receptors increasingly has drawn attention to the important
contribution of the extracellular domains either alone or in
combination with the transmembrane domains toward the interaction with
the naturally occurring agonist (Strader et al., 1994
).
Although it is difficult to interpret whether point mutations that
decrease agonist affinity do so on the basis of direct ligand
interaction versus indirect changes in local conformation, the results
of this and previous studies of CCKAR and CCKBR interaction with their
structurally related agonists, CCK and gastrin, together suggest that
both ligands interact predominantly with multiple sites within several
extracellular domains and to a lesser extent with the outer third of
TMI and TMIII (Kopin, et al., 1995
; Poirot and Wank, 1996
;
Schmitz et al., 1996
; Kennedy et al., 1997
; Wu et al., 1997
). In addition to the proposed tight helical
packing of the transmembrane domains (Baldwin, 1993
; Schertler et
al., 1993
), data in this study suggest that the apparently distant sites of interaction of CCK and gastrin with the amino-terminal, first
and second ECLs, and transmembrane domains of CCK receptors may
actually be reasonably close by virtue of a disulfide bridge between
two highly conserved cysteines located in the middle of ECL2 and ECL1
just at the top of TMIII (Fig. 1). The present study also supports the
hypothesis that the ligand binding site for CCK differs for the two CCK
receptor subtypes as well as between CCK and gastrin within the CCKBR.
| |
Acknowledgments |
|---|
We thank Michelle Bouisson (INSERM, Toulouse, France) for DNA sequencing.
| |
Footnotes |
|---|
Received December 2, 1997; Accepted April 15, 1998
This work was supported in part by a grant from the Association pour la Recherche sur le Cancer (ARC 6234) and a grant from the Region Midi-Pyrénées. S.S.-P. is in charge of research for Centre National de la Recherche Scientifique.
Send reprint requests to: Dr. Stephen A. Wank, National Institutes of Health, Building 10, Room 9C-103, Bethesda, MD 20892-1804. E-mail: stevew{at}bdg10.niddk.nih.gov
| |
Abbreviations |
|---|
CCK, cholecystokinin;
CCK-8, cholecystokinin octapeptide;
CCKAR, cholecystokinin receptor type A;
CCKBR, cholecystokinin receptor type B;
ECL, extracellular loop;
TM, transmembrane;
BH, Bolton-Hunter;
DMEM, Dulbecco's modified
Eagle's medium;
PBS, phosphate-buffered saline;
BSA, bovine serum
albumin;
EGTA, ethylene glycol bis(
-aminoethyl
ether)-N,N,N',N'-tetraacetic
acid;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
IP, inositol phosphate(s).
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
N. Gonzalez, S. J. Hocart, S. Portal-Nunez, S. A. Mantey, T. Nakagawa, E. Zudaire, D. H. Coy, and R. T. Jensen Molecular Basis for Agonist Selectivity and Activation of the Orphan Bombesin Receptor Subtype 3 Receptor J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 463 - 474. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Stewart, R. Sellar, D. J. Wilson, R. P. Millar, and Z.-L. Lu Identification of a Novel Ligand Binding Residue Arg38(1.35) in the Human Gonadotropin-Releasing Hormone Receptor Mol. Pharmacol., January 1, 2008; 73(1): 75 - 81. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Paillasse, C. Deraeve, P. de Medina, L. Mhamdi, G. Favre, M. Poirot, and S. Silvente-Poirot Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation Mol. Pharmacol., December 1, 2006; 70(6): 1935 - 1945. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dufresne, C. Seva, and D. Fourmy Cholecystokinin and gastrin receptors. Physiol Rev, July 1, 2006; 86(3): 805 - 847. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Klco, G. V. Nikiforovich, and T. J. Baranski Genetic Analysis of the First and Third Extracellular Loops of the C5a Receptor Reveals an Essential WXFG Motif in the First Loop J. Biol. Chem., April 28, 2006; 281(17): 12010 - 12019. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Hawtin, V. J. Wesley, J. Simms, C. C. H. Argent, K. Latif, and M. Wheatley The N-Terminal Juxtamembrane Segment of the V1a Vasopressin Receptor Provides Two Independent Epitopes Required for High-Affinity Agonist Binding and Signaling Mol. Endocrinol., November 1, 2005; 19(11): 2871 - 2881. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Langer, I. G. Tikhonova, M.-A. Travers, E. Archer-Lahlou, C. Escrieut, B. Maigret, and D. Fourmy Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin J. Biol. Chem., June 10, 2005; 280(23): 22198 - 22204. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Morel, G. Ibarz, C. Oiry, E. Carnazzi, G. Berge, D. Gagne, J.-C. Galleyrand, and J. Martinez Cross-interactions of Two p38 Mitogen-activated Protein (MAP) Kinase Inhibitors and Two Cholecystokinin (CCK) Receptor Antagonists with the CCK1 Receptor and P38 MAP Kinase J. Biol. Chem., June 3, 2005; 280(22): 21384 - 21393. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dong, E. M. Hadac, D. I. Pinon, and L. J. Miller Differential Spatial Approximation between Cholecystokinin Residue 30 and Receptor Residues in Active and Inactive Conformations Mol. Pharmacol., June 1, 2005; 67(6): 1892 - 1900. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gales, M. Poirot, J. Taillefer, B. Maigret, J. Martinez, L. Moroder, C. Escrieut, L. Pradayrol, D. Fourmy, and S. Silvente-Poirot Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site-Directed Mutagenesis, and Structure/Affinity Studies Mol. Pharmacol., May 1, 2003; 63(5): 973 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tokita, S. J. Hocart, D. H. Coy, and R. T. Jensen Molecular Basis of the Selectivity of Gastrin-Releasing Peptide Receptor for Gastrin-Releasing Peptide Mol. Pharmacol., June 1, 2002; 61(6): 1435 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Holicky, E. M. Hadac, X.-Q. Ding, and L. J. Miller Molecular characterization and organ distribution of type A and B cholecystokinin receptors in cynomolgus monkey Am J Physiol Gastrointest Liver Physiol, August 1, 2001; 281(2): G507 - G514. [Abstract] [Full Text] [PDF] |
||||
![]() |